ERYTHROMYCIN ETHYLSUCCINATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin Ethylsuccinate, and when can generic versions of Erythromycin Ethylsuccinate launch?
Erythromycin Ethylsuccinate is a drug marketed by Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Par Pharm Inc, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Aurobindo Pharma Usa, Azurity, and Barr. and is included in fourteen NDAs.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for ERYTHROMYCIN ETHYLSUCCINATE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 54 |
Clinical Trials: | 1 |
Patent Applications: | 1,779 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ERYTHROMYCIN ETHYLSUCCINATE? | ERYTHROMYCIN ETHYLSUCCINATE excipients list |
DailyMed Link: | ERYTHROMYCIN ETHYLSUCCINATE at DailyMed |
Recent Clinical Trials for ERYTHROMYCIN ETHYLSUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Florida | Phase 2 |
Metabolic Solutions Inc. | Phase 2 |
Pharmacology for ERYTHROMYCIN ETHYLSUCCINATE
Drug Class | Macrolide Antimicrobial Macrolide |
Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN ETHYLSUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN ETHYLSUCCINATE
US Patents and Regulatory Information for ERYTHROMYCIN ETHYLSUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal Pharms | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 211204-001 | Nov 1, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Pharmafair | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062558-001 | Mar 15, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-002 | Nov 21, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ani Pharms | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 062055-003 | Nov 2, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Dista | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062177-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |